Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6781
+0.0150 (2.26%)
At close: Dec 30, 2025, 4:00 PM EST
0.6752
-0.0029 (-0.43%)
After-hours: Dec 30, 2025, 4:44 PM EST
Vistagen Therapeutics Employees
As of March 31, 2025, Vistagen Therapeutics had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 17 or 42.50% compared to the previous year.
Employees
57
Change (1Y)
17
Growth (1Y)
42.50%
Revenue / Employee
$12,649
Profits / Employee
-$1,091,860
Market Cap
26.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 57 | 17 | 42.50% |
| Mar 31, 2024 | 40 | 6 | 17.65% |
| Mar 31, 2023 | 34 | -2 | -5.56% |
| Mar 31, 2022 | 36 | 15 | 71.43% |
| Mar 31, 2021 | 21 | 12 | 133.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VTGN News
- 13 days ago - Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study - Benzinga
- 13 days ago - Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 4 weeks ago - Vistagen Appoints Nick Tressler as Chief Financial Officer - Business Wire
- 4 weeks ago - Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Business Wire
- 6 weeks ago - Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 - Seeking Alpha
- 6 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update - Business Wire
- 7 weeks ago - Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 - Business Wire